Welcome to our dedicated page for Elevation Oncology SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elevation Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elevation Oncology's regulatory disclosures and financial reporting.
Nasdaq Stock Market LLC has filed Form 25 with the SEC to remove Elevation Oncology, Inc. (ELEV) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.
The notification, signed by AVP Tara Petta on 23 Jul 2025, states that Nasdaq has reasonable grounds to believe it satisfies all requirements for the filing and has complied with its own rules pursuant to Rule 12d2-2.
Once effective, the filing will strike the company’s sole listed security—its common stock—from Nasdaq’s official list and terminate its Section 12(b) registration.
Elevation Oncology (ELEV) has ceased to be a public company. On 23-Jul-2025, Concentra Biosciences closed its acquisition via a Section 251(h) short-form merger after its subsidiary accepted 67.09% of shares tendered at $0.36 cash per share plus one non-transferable contingent value right (CVR). All remaining shares were converted into the same consideration at the effective time.
Immediately following the closing, ELEV requested Nasdaq suspend trading and filed for delisting (Form 25) and deregistration (Form 15). All equity awards were treated per the merger terms: in-the-money options received cash for intrinsic value plus a CVR; out-of-the-money options were cancelled; RSUs vested and received cash and a CVR; 22.05 m warrants were cashed out at their Black-Scholes value.
The transaction triggered a change in control. All six legacy directors resigned and Concentra’s slate, led by Kevin Tang (CEO), assumed board and officer roles. Interim CEO/CFO Tammy Furlong was terminated without cause and entered a separation agreement providing 12 months base salary, 100% target bonus, an additional $600k cash payment and full accelerated vesting.
The certificate of incorporation and bylaws were amended and restated, completing ELEV’s transition to a wholly owned Concentra subsidiary.